Phase II Trial of Atezolizumab in BCG-Unresponsive Non-muscle Invasive Bladder Cancer
N
Nabil Adra, MD
Primary Investigator
Recruiting
18-100 years
All
Phase
N/A
2 Locations
Brief description of study
This phase II trial studies how well atezolizumab works in treating patients with non-muscle invasive bladder cancer that has come back and has not responded to treatment with Bacillus Calmette-Guerin (BCG).
Detailed description of study
The purpose of this study is to estimate complete response at 25 weeks after registration for those with a carcinoma in situ (CIS) component and to evaluate event-free survival at 18 months in patients with BCG-unresponsive high-risk non-muscle invasive bladder cancer (Ta/T1/CIS) treated with atezolizumab.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: bladder cancer,Bladder Urothelial Carcinoma,non-muscle invasive bladder cancer
-
Age: Between 18 Years - 100 Years
-
Gender: All
Inclusion Criteria
In order to be eligible to take part in this trial, patients must meet the following criteria:
- Patients must have histologically proven, recurrent, non-muscle invasive urothelial carcinoma of the bladder within 60 days prior to registration; the carcinoma must be stage T1 high-grade, stage CIS, or stage Ta high-grade
- Patients with mixed urothelial carcinoma and a glandular and/or squamous component will be eligible for the trial, but the presence of other histologic variants, pure adenocarcinoma, or pure squamous cell carcinoma, will make a patient ineligible
For a full list of participation criteria, please visit clinicaltrials.gov.
Additional Information:Participants will not be paid for their participation.
Updated on
01 Aug 2024.
Study ID: 1804004016 (S1605)
Find a site
,
You have contacted , on
Your message has been sent to the study team at ,
A copy of the message has been sent to your email
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
Primary Contact
